The observed safety profile was consistent with earlier findings in clinical studies that led to the approval of bosentan (Tracleer 125mg bid) in pulmonary arterial hypertension (PAH).
The company will fully analyze the data generated in this study with close to 90 patients and discuss the detailed findings with key medical experts in the field. The company will also continue to evaluate the potential use of endothelin receptor antagonism in pre-clinical cancer models.